解放军医药杂志2015，Vol.27Issue(9)：77-81,5.DOI:10.3969/j.issn.2095-140X.2015.09.016
失代偿期丙型肝炎肝硬化脾栓塞术后聚乙二醇干扰素联合利巴韦林抗病毒治疗效果观察
Observation of Antiviral Effect of Pegylated Interferon Combined with Ribavirin on Decompensated Hepatitis C Cirrhosis Patients after Splenic Embolization
摘要
Abstract
Objective To investigate the feasibility and safety of antiviral effect of Pegylated interferon combined with Ribavirin on decompensated hepatitis C cirrhosis patients after splenic embolization. Methods A total of 108 de-compensated hepatitis C cirrhosis patients after splenic embolization during January 2011 and December 2013 were divid-ed into observation group (n=60) and control group (n=48) according to therapeutic method. All patients received basic supporting therapy, and then the observation group was treated with Pegylated interferon combined with Ribavirin, while the control group was treated with Ribavirin only. The therapic time in the two groups was 24 weeks. The results of routine blood test, liver functions, antiviral effects and incidence rates of adverse reactions in two groups were compared after treatment for 4, 12 and 24 weeks. Results One-way Anova of repeated measures showed that improvements of all indexes in observation group were superior to those in control group excepted for red blood cell ( RBC, P<0. 05 or P<0. 01), and the differences in values of white blood cell, platelet, albumin, Child-Pugh score, alanine transarninase ( ALT) , total bilirubin ( TBIL) and aspartate aminotransferase ( AST) in the two groups were statistically significant with the time went by at all time points ( P<0. 01 ) . Multifactor Anova of repeated measures showed that the differences in values of white blood cell, platelet, albumin, Child-Pugh score, ALT, TBIL and AST in the two groups were statistically significant (P<0. 05 or P<0. 01). The rates of rapid virological response (RVR), early virological response (EVR), end treatment of virological response ( ETVR) and sequential virological response ( SVR) in observation group were sig-nificantly higher than those in control group (P<0. 05), and the differences in all response rates between patients with non-genotype 1 and patients with genotype 1 in the two groups were statistically significant (P<0. 05 or P<0. 01). The differences in all response rates between patients with non-genotype 1 and patients with genotype 1 in the observation group were statistically significant (P<0. 05 or P<0. 01), while the difference in SVR rate between patients with non-genotype 1 and patients with genotype 1 in the control group was statistically significant (P<0. 05). and the difference in incidence rate of adverse reactions in the two groups were not statistically significant (P>0. 05). Conclusion The anti-viral effect of Pegylated interferon combined with Ribavirin on better decompensated hepatitis C cirrhosis patients after splenic embolization can improve the patients' routine blood and liver functions with higher virus-response rate and control-lable adverse reactions.关键词
丙型肝炎/肝硬化/干扰素类/利巴韦林/抗病毒药Key words
Hepatitis C/Liver cirrhosis/Interferons/Ribavirin/Antiviral agents分类
医药卫生引用本文复制引用
熊锦华,曹建彪,李绍祥,陈力强,范公忍..失代偿期丙型肝炎肝硬化脾栓塞术后聚乙二醇干扰素联合利巴韦林抗病毒治疗效果观察[J].解放军医药杂志,2015,27(9):77-81,5.基金项目
中国肝炎防治基金会王宝恩肝纤维化研究基金(xjs201302) （xjs201302）
